WO2013036973A3 - Methods and compositions for controlling assembly of viral proteins - Google Patents
Methods and compositions for controlling assembly of viral proteins Download PDFInfo
- Publication number
- WO2013036973A3 WO2013036973A3 PCT/US2012/054534 US2012054534W WO2013036973A3 WO 2013036973 A3 WO2013036973 A3 WO 2013036973A3 US 2012054534 W US2012054534 W US 2012054534W WO 2013036973 A3 WO2013036973 A3 WO 2013036973A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- core proteins
- compositions
- methods
- assembly
- viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014529962A JP2014527072A (en) | 2011-09-09 | 2012-09-10 | Methods and compositions for controlling the assembly of viral proteins |
AU2012305714A AU2012305714A1 (en) | 2011-09-09 | 2012-09-10 | Methods and compositions for controlling assembly of viral proteins |
CA2847888A CA2847888A1 (en) | 2011-09-09 | 2012-09-10 | Methods and compositions for controlling assembly of viral proteins |
EP12829920.3A EP2747774A4 (en) | 2011-09-09 | 2012-09-10 | Methods and compositions for controlling assembly of viral proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161532986P | 2011-09-09 | 2011-09-09 | |
US61/532,986 | 2011-09-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013036973A2 WO2013036973A2 (en) | 2013-03-14 |
WO2013036973A3 true WO2013036973A3 (en) | 2013-07-11 |
Family
ID=47832822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/054534 WO2013036973A2 (en) | 2011-09-09 | 2012-09-10 | Methods and compositions for controlling assembly of viral proteins |
Country Status (6)
Country | Link |
---|---|
US (2) | US8865188B2 (en) |
EP (1) | EP2747774A4 (en) |
JP (1) | JP2014527072A (en) |
AU (1) | AU2012305714A1 (en) |
CA (1) | CA2847888A1 (en) |
WO (1) | WO2013036973A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
JP2014527072A (en) | 2011-09-09 | 2014-10-09 | バイオメド リアルティー, エル.ピー. | Methods and compositions for controlling the assembly of viral proteins |
CA2936092A1 (en) * | 2013-01-23 | 2014-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Stabilized hepatitis b core polypeptide |
GB201506870D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
CN106279379B (en) * | 2016-09-13 | 2020-05-22 | 华兰生物工程股份有限公司 | Immunogen HM4-M2e, and preparation method and application thereof |
TWI634899B (en) * | 2016-11-22 | 2018-09-11 | 國立臺灣大學 | Vaccine composition comprising hepatitisb virus-like particle as adjuvant |
CN107488217A (en) * | 2017-09-13 | 2017-12-19 | 华兰生物疫苗有限公司 | A kind of polypeptide, immunogenic conjugate and influenza vaccines |
GB201716254D0 (en) * | 2017-10-05 | 2017-11-22 | Univ Leuven Kath | Live-attenuated flaviruses with heterologous antigens |
EP3865145A4 (en) * | 2018-10-12 | 2022-08-31 | Riken | Hepatitis b virus replication inhibitor and pharmaceutical composition comprising same for treating hepatitis b |
CN113508125A (en) * | 2018-12-28 | 2021-10-15 | 小利兰·斯坦福大学托管委员会 | Engineered hepatitis b core polypeptides |
CN110125434B (en) * | 2019-05-14 | 2022-07-29 | 东南大学 | Preparation method of photo-thermal gold nano material |
US20230083273A1 (en) * | 2020-02-13 | 2023-03-16 | The Trustees Of Indiana University | Hepadnavirus capsid protein heterodimers and virus-like particles |
GB202210507D0 (en) * | 2022-07-18 | 2022-08-31 | Univ Dundee | Virus-like particles, heterodimeric capsid proteins and methods of production thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292174A1 (en) * | 2004-05-25 | 2006-12-28 | De Los Rios Miguel A | Self-assembling nanoparticle drug delivery system |
US20070269370A1 (en) * | 2006-04-07 | 2007-11-22 | Davis Claude G | Compositions and methods for treating B-cell malignancies |
US20090226525A1 (en) * | 2007-04-09 | 2009-09-10 | Chimeros Inc. | Self-assembling nanoparticle drug delivery system |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816564A (en) | 1986-01-31 | 1989-03-28 | Merck & Co., Inc. | Method for producing hepatitis B virus proteins in yeast |
IL90161A0 (en) | 1988-05-13 | 1989-12-15 | Phillips Petroleum Co | Expression of hepatitis b s and pres2 proteins in methylotrophic yeasts |
US5620689A (en) | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
CA2089497A1 (en) | 1990-08-15 | 1992-02-16 | Lendon Payne | Self-assembling replication defective hybrid virus particles |
WO1993000103A1 (en) | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
DK0693924T4 (en) | 1993-02-22 | 2008-08-04 | Abraxis Bioscience Inc | Process for (in vivo) delivery of biological materials and compositions suitable therefor |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
CA2190121A1 (en) | 1994-03-15 | 1995-09-21 | Edith Mathiowitz | Polymeric gene delivery system |
CA2191750C (en) | 1994-05-31 | 2008-06-10 | Jan C. Wilschut | Virosome-mediated intracellular delivery of therapeutic agents |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US6613749B1 (en) | 1994-07-26 | 2003-09-02 | Imperial College Innovations Limited | Papovavirus pseudocapsids and use thereof for exogenous material transfer |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
DE69633565T3 (en) | 1995-06-15 | 2013-01-17 | Crucell Holland B.V. | PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRES, FOR USE IN GENE THERAPY |
ATE382694T1 (en) | 1995-11-28 | 2008-01-15 | Genvec Inc | VECTORS AND METHODS OF GENE TRANSFER INTO CELLS |
US6284494B1 (en) | 1995-12-12 | 2001-09-04 | The University Of British Columbia | Methods and compositions for synthesis of oligosaccharides using mutant glycosidase enzymes |
WO1997037680A1 (en) | 1996-04-05 | 1997-10-16 | The Board Of Trustees Of The University Of Illinois | Macromolecular complexes for drug delivery |
FR2749323B1 (en) | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | PSEUDO-PARTICLES VIRALES USEFUL AS A VECTOR OF NUCLEIC ACID DELIVERY |
WO1998011916A1 (en) | 1996-09-18 | 1998-03-26 | The Board Of Regents Of The University Of Texas System | Viral defective interfering particles and uses thereof |
DE69739268D1 (en) | 1996-11-08 | 2009-04-02 | Us Gov Health & Human Serv | PREPARATION AND CLEANING OF HEPATITIS C VIRUS-RELATED PARTICLES |
US6180389B1 (en) | 1997-01-03 | 2001-01-30 | The Research And Development Institute, Inc. | Virion-constrained nanoparticles comprising a plant virion coat protein shell and encapsulated guest molecules |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6287857B1 (en) | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
EP1053342A2 (en) | 1998-02-09 | 2000-11-22 | Genzyme Corporation | Nucleic acid delivery vehicles |
EP1054689B1 (en) | 1998-02-12 | 2003-09-10 | Immune Complex, Corporation | Strategically modified hepatitis b core proteins and their derivatives |
CN1255895C (en) | 1998-08-05 | 2006-05-10 | 索尼公司 | Composition for electrolyte, electrolyte and process for producing same, and cell contg. same |
AU5556799A (en) | 1998-08-12 | 2000-03-06 | University Of Virginia Patent Foundation | Assay for assembly of herpes simplex virus capsid |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
EP1845163A3 (en) | 1998-11-05 | 2007-10-31 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype l nucleic acid sequences, vetors and host cells containing same |
IL143475A0 (en) | 1998-12-04 | 2002-04-21 | Biogen Inc | Hepatitis b virus core antigen particles and vaccines and pharmaceutical compositions containing the same |
US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
JP2003504014A (en) | 1999-06-30 | 2003-02-04 | エボテック オーアーイー アクチェンゲゼルシャフト | Viral particles, their preparation and preferably their use in pharmaceutical screening and functional genomes |
US20020064520A1 (en) | 1999-08-19 | 2002-05-30 | Yanina Rozenberg | Targeted artificial gene delivery |
US6593308B2 (en) | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
US6602932B2 (en) | 1999-12-15 | 2003-08-05 | North Carolina State University | Nanoparticle composites and nanocapsules for guest encapsulation and methods for synthesizing same |
GB9930533D0 (en) | 1999-12-23 | 2000-02-16 | Mitsubishi Tokyo Pharm Inc | Nucleic acid delivery |
US6616944B2 (en) | 2000-03-08 | 2003-09-09 | Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh | Self-assembling colloidal carriers for protein delivery |
US7332337B2 (en) | 2000-05-16 | 2008-02-19 | Galapagos Nv | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
NZ524070A (en) | 2000-07-19 | 2008-05-30 | Univ California | Methods for therapy of neurodegenerative disease of the non-human brain |
US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
WO2002044204A2 (en) | 2000-12-01 | 2002-06-06 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Cell-free assembly of lentiviral capsids |
TR200401292T3 (en) | 2000-12-01 | 2004-07-21 | Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften | the rnaágirişimineáyoláaçanáküçükárnaámolekül |
EP1219705B1 (en) | 2000-12-29 | 2007-11-28 | Evotec AG | Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics |
CA2450470C (en) | 2001-06-22 | 2012-08-28 | The Trustees Of The University Of Pennsylvania | Method for rapid screening of bacterial transformants and novel simian adenovirus proteins |
US7101995B2 (en) | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
WO2003022869A2 (en) | 2001-09-06 | 2003-03-20 | Progenics Pharmaceuticals, Inc. | Human immunodeficiency virus envelope clycoprotein mutants and uses thereof |
US7148343B2 (en) | 2001-10-12 | 2006-12-12 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify RNA |
EP1944043A1 (en) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
CA2466431C (en) | 2001-11-21 | 2014-08-05 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
EP3517134B1 (en) | 2001-12-17 | 2024-01-17 | The Trustees of the University of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same and uses therefor |
BR0311995A (en) | 2002-06-20 | 2005-04-05 | Cytos Biotechnology Ag | Virus-like particles packaged for use as adjuvants: Method of preparation and use |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
EP1447079A1 (en) | 2003-02-15 | 2004-08-18 | Fraunhofer-Gesellschaft für angewandte Forschung e.V. | Vesicles with chimeric receptors to induce a targeted T-cell response in vivo |
AU2003287526A1 (en) | 2002-11-06 | 2004-06-03 | Protein-stabilized liposomal formulations of pharmaceutical agents | |
JP2004175665A (en) | 2002-11-22 | 2004-06-24 | Japan Science & Technology Agency | Protein hollow nanoparticle and drug using the same |
DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
US7332321B2 (en) | 2003-10-15 | 2008-02-19 | Board Of Regents, The University Of Texas System | Viral fibers |
CA2572129A1 (en) | 2004-07-01 | 2006-01-12 | The Circle For The Promotion Of Science And Engineering | Viral particle-like construct and method of forming the same under physiological conditions |
GB0416487D0 (en) | 2004-07-23 | 2004-08-25 | Isis Innovation | Modified virus |
AU2005282352B2 (en) | 2004-09-09 | 2011-12-01 | The General Hospital Corporation | Modulating phosphatase activity in cardiac cells |
EP1799251A2 (en) | 2004-09-17 | 2007-06-27 | Chr. Hansen A/S | Chimeric phage-derived particles, methods for their production and use |
CN2763975Y (en) | 2004-12-11 | 2006-03-08 | 鸿富锦精密工业(深圳)有限公司 | Heat-pipe radiator |
AU2005316458B2 (en) | 2004-12-17 | 2011-04-07 | Beth Israel Deaconess Medical Center | Compositions for bacterial mediated gene silencing and methods of using same |
WO2006088229A1 (en) | 2005-02-16 | 2006-08-24 | The Circle For The Promotion Of Science And Engineering | Modified virus capsid protein and the use thereof |
US20070160628A1 (en) * | 2005-08-31 | 2007-07-12 | Birkett Ashley J | Stabilized virus-like particles and epitope display systems |
WO2008048288A2 (en) | 2005-11-09 | 2008-04-24 | Montana State University | Novel nanoparticles and use thereof |
WO2007126764A2 (en) | 2006-03-27 | 2007-11-08 | The Regents Of The University Of California | Chemically modified viral capsids as targeted delivery vectors for diagnostic and therapeutic agents |
WO2008027084A2 (en) | 2006-04-28 | 2008-03-06 | The Trustees Of The University Of Pennsylvania | Modified aav vectors having reduced capsid immunogenicity and use thereof |
DE602007004470D1 (en) | 2006-04-28 | 2010-03-11 | Univ Pennsylvania | MODIFIED ADENOVIRUS HEXON PROTEIN AND APPLICATIONS THEREOF |
US20090238885A1 (en) | 2006-05-22 | 2009-09-24 | Nizo Food Research B.V. | Protein encapsulated particles |
CA2664919A1 (en) | 2006-08-08 | 2008-02-21 | Board Of Regents Of The University Of Texas | Multistage delivery of active agents |
WO2008024427A2 (en) | 2006-08-23 | 2008-02-28 | Science & Technology Corporation @ Unm | A virus-like platform for rapid vaccine discovery |
CA2664418A1 (en) | 2006-09-28 | 2008-04-03 | Cytos Biotechnology Ag | Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases |
EP2120894A1 (en) | 2006-10-25 | 2009-11-25 | Universidade de Coimbra | Oral submicron particle delivery system for proteins and process for its production |
CA2597878A1 (en) * | 2007-09-13 | 2009-03-13 | Ankegens Laboratories | Capsid protein and use therefore |
WO2010042755A2 (en) | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Chimeric therapeutics, compositions, and methods for using same |
WO2010042743A2 (en) * | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Chimeric multiplexes, compositions, and methods for using same |
WO2010042749A2 (en) | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Chimeric therapeutics, compositions, and methods for using same |
WO2010042751A2 (en) | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Chimeric therapeutics, compositions, and methods for using same |
WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
JP2014527072A (en) | 2011-09-09 | 2014-10-09 | バイオメド リアルティー, エル.ピー. | Methods and compositions for controlling the assembly of viral proteins |
-
2012
- 2012-09-10 JP JP2014529962A patent/JP2014527072A/en active Pending
- 2012-09-10 AU AU2012305714A patent/AU2012305714A1/en not_active Abandoned
- 2012-09-10 CA CA2847888A patent/CA2847888A1/en not_active Abandoned
- 2012-09-10 WO PCT/US2012/054534 patent/WO2013036973A2/en active Application Filing
- 2012-09-10 EP EP12829920.3A patent/EP2747774A4/en not_active Withdrawn
- 2012-09-10 US US13/609,234 patent/US8865188B2/en not_active Expired - Fee Related
-
2014
- 2014-10-17 US US14/516,956 patent/US20150252081A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292174A1 (en) * | 2004-05-25 | 2006-12-28 | De Los Rios Miguel A | Self-assembling nanoparticle drug delivery system |
US20070269370A1 (en) * | 2006-04-07 | 2007-11-22 | Davis Claude G | Compositions and methods for treating B-cell malignancies |
US20090226525A1 (en) * | 2007-04-09 | 2009-09-10 | Chimeros Inc. | Self-assembling nanoparticle drug delivery system |
Non-Patent Citations (1)
Title |
---|
See also references of EP2747774A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP2014527072A (en) | 2014-10-09 |
US8865188B2 (en) | 2014-10-21 |
AU2012305714A1 (en) | 2014-03-27 |
EP2747774A4 (en) | 2015-02-11 |
US20150252081A1 (en) | 2015-09-10 |
CA2847888A1 (en) | 2013-03-14 |
WO2013036973A2 (en) | 2013-03-14 |
EP2747774A2 (en) | 2014-07-02 |
US20130156818A1 (en) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013036973A3 (en) | Methods and compositions for controlling assembly of viral proteins | |
WO2012072096A8 (en) | Method for cellular rna expression | |
AU2012327781B2 (en) | Modified Y zeolite, method for preparing same, and use thereof | |
WO2014125374A3 (en) | Highly galactosylated anti-tnf-alpha antibodies and uses thereof | |
WO2014014835A3 (en) | Criystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
WO2012016227A3 (en) | Antibodies with modified isoelectric points | |
EP3892709A3 (en) | Variants and compositions comprising variants with high stability in presence of a chelating agent | |
WO2014005019A3 (en) | Cells for producing recombinant iduronate-2-sulfatase | |
WO2012096461A3 (en) | Composition for suspension culturing of stem cells | |
JP2011078421A5 (en) | ||
WO2012068317A3 (en) | Methods for producing recombinant proteins | |
WO2011080301A3 (en) | Strains and method for the production of methionine | |
WO2012017323A3 (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by hiv or associated with hiv | |
IN2014CN03077A (en) | ||
WO2009099877A3 (en) | Closterovirus vectors and methods | |
WO2011104315A3 (en) | Immunoglobulin preparation and storage system for an immunoglobulin preparation | |
WO2010042755A3 (en) | Chimeric therapeutics, compositions, and methods for using same | |
WO2010042751A3 (en) | Chimeric therapeutics, compositions, and methods for using same | |
WO2013027977A3 (en) | Composition for breaking down l-asparagine comprising l-asparaginase, and production method for l-asparaginase | |
WO2013006734A8 (en) | Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity | |
WO2012151242A3 (en) | Lignin-based nanostructures | |
WO2012122465A3 (en) | Yeast with reduced 2,3-butanediol accumulation | |
MX2012014163A (en) | Methods of treatment. | |
WO2014145236A3 (en) | The use of sdf-1 to mitigate scar formation | |
WO2014037519A3 (en) | Compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12829920 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2847888 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014529962 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2012829920 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012829920 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2012305714 Country of ref document: AU Date of ref document: 20120910 Kind code of ref document: A |